Wolverine Trading’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-8,600
| Closed | -$1.29M | – | 5697 |
|
|
2025
Q2 | $1.29M | Sell |
8,600
-6,000
| -41% | -$800K | ﹤0.01% | 2070 |
|
|
2025
Q1 | $2.27M | Sell |
14,600
-4,600
| -24% | -$771K | ﹤0.01% | 1521 |
|
|
2024
Q4 | $3.52M | Sell |
19,200
-2,500
| -12% | -$482K | ﹤0.01% | 1475 |
|
|
2024
Q3 | $4.3M | Buy |
21,700
+10,100
| +87% | +$2.1M | ﹤0.01% | 1144 |
|
|
2024
Q2 | $2.4M | Buy |
11,600
+3,700
| +47% | +$838K | ﹤0.01% | 1474 |
|
|
2024
Q1 | $2.14M | Sell |
7,900
-1,500
| -16% | -$358K | ﹤0.01% | 1565 |
|
|
2023
Q4 | $2.22M | Buy |
9,400
+1,700
| +22% | +$334K | ﹤0.01% | 1634 |
|
|
2023
Q3 | $1.51M | Buy |
7,700
+2,800
| +57% | +$575K | ﹤0.01% | 1799 |
|
|
2023
Q2 | $1.02M | Buy |
+4,900
| New | +$975K | ﹤0.01% | 1995 |
|
|
2023
Q1 | – | Sell |
-4,400
| Closed | -$959K | – | 4337 |
|
|
2022
Q4 | $959K | Buy |
4,400
+1,000
| +29% | +$218K | ﹤0.01% | 1875 |
|
|
2022
Q3 | $646K | Buy |
3,400
+500
| +17% | +$108K | ﹤0.01% | 2376 |
|
|
2022
Q2 | $636K | Sell |
2,900
-4,300
| -60% | -$1.05M | ﹤0.01% | 2318 |
|
|
2022
Q1 | $2.09M | Sell |
7,200
-3,700
| -34% | -$1.14M | ﹤0.01% | 1734 |
|
|
2021
Q4 | $4.1M | Sell |
10,900
-3,100
| -22% | -$1.2M | ﹤0.01% | 1281 |
|
|
2021
Q3 | $5.92M | Buy |
14,000
+6,200
| +79% | +$2.57M | 0.01% | 1179 |
|
|
2021
Q2 | $2.9M | Buy |
7,800
+3,900
| +100% | +$1.3M | ﹤0.01% | 1625 |
|
|
2021
Q1 | $1.12M | Buy |
3,900
+2,700
| +225% | +$751K | ﹤0.01% | 2602 |
|
|
2020
Q4 | $298K | Sell |
1,200
-1,800
| -60% | -$429K | ﹤0.01% | 3751 |
|
|
2020
Q3 | $669K | Sell |
3,000
-8,100
| -73% | -$1.68M | ﹤0.01% | 2493 |
|
|
2020
Q2 | $1.88M | Buy |
11,100
+2,500
| +29% | +$399K | 0.01% | 1463 |
|
|
2020
Q1 | $1.12M | Buy |
8,600
+4,000
| +87% | +$600K | ﹤0.01% | 1816 |
|
|
2019
Q4 | $698K | Sell |
4,600
-500
| -10% | -$69.2K | ﹤0.01% | 2757 |
|
|
2019
Q3 | $676K | Buy |
+5,100
| New | +$684K | ﹤0.01% | 2309 |
|
|
2018
Q3 | – | Sell |
-4,300
| Closed | -$459K | – | 5031 |
|
|
2018
Q2 | $459K | Hold |
4,300
| – | – | ﹤0.01% | 3191 |
|
|
2018
Q1 | $459K | Buy |
4,300
+200
| +5% | +$21.6K | ﹤0.01% | 3191 |
|
|
2017
Q4 | $449K | Buy |
+4,100
| New | +$446K | ﹤0.01% | 3134 |
|
|
2016
Q3 | – | Sell |
-2,600
| Closed | -$210K | – | 4643 |
|
|
2016
Q2 | $210K | Buy |
+2,600
| New | +$214K | ﹤0.01% | 3229 |
|
Other funds holding CRL
AI
Wolverine Trading's CRL Position: Q3 2025 in Review
Wolverine Trading sold out of Charles River Laboratories (CRL) in Q3 2025, closing a stake of 3,628 shares — an estimated $544K sold.
Wolverine Trading first reported a position in CRL in Q1 2018 and held it in 16 quarters. The position peaked at $2.26M in Q2 2021. 554 funds tracked by Wall St. Rank hold CRL as of Q3 2025.
- Wolverine Trading reported no remaining Charles River Laboratories position as of Q3 2025 after selling out during the quarter.
- Wolverine Trading sold 3,628 Charles River Laboratories shares in Q3 2025, an estimated $544K.
- Wolverine Trading first reported a position in Charles River Laboratories in Q1 2018 and held it in 16 quarters.
- Wolverine Trading's Charles River Laboratories position peaked at $2.26M in Q2 2021.
- 554 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2025.
Based on Wolverine Trading's 13F filing for Q3 2025, filed 14 Nov 2025.